U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. MasterPharm LLC - 07/07/2017
  1. Warning Letters

CLOSEOUT LETTER

MasterPharm LLC

Recipient:
MasterPharm LLC

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

New Jersey District
10 Waterview Blvd. 3rd Floor
Parsippany, New Jersey 07054

 
 

July 7, 2017

Stephen S. Laddy, CEO
MasterPharm LLC
11502 Liberty Ave, 2nd Floor
South Richmond Hill, NY 11419-1902

Dear Mr. Laddy:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL #: NYK-2016-18] dated January 8, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Diana Amador-Toro
District Director
New Jersey District Office
Office of Regulatory Affairs
U.S. Food and Drug Administration
 

Back to Top